Monday, January 25, 2021
Corporate Compliance Insights
  • Home
  • About
    • About CCI
    • Writing for CCI
    • NEW: CCI Press – Book Publishing
    • Advertise With Us
  • Articles
    • See All Articles
    • NEW: COVID-Related
    • Compliance
    • Ethics
    • Risk
    • FCPA
    • Governance
    • Fraud
    • Internal Audit
    • HR Compliance
    • Cybersecurity
    • Data Privacy
    • Financial Services
    • Leadership and Career
  • Vendor News
  • Jobs
  • Events
    • Webinars & Events
    • Submit an Event
  • Downloads
    • eBooks
    • Whitepapers
  • Podcasts
  • Videos
  • Subscribe
No Result
View All Result
  • Home
  • About
    • About CCI
    • Writing for CCI
    • NEW: CCI Press – Book Publishing
    • Advertise With Us
  • Articles
    • See All Articles
    • NEW: COVID-Related
    • Compliance
    • Ethics
    • Risk
    • FCPA
    • Governance
    • Fraud
    • Internal Audit
    • HR Compliance
    • Cybersecurity
    • Data Privacy
    • Financial Services
    • Leadership and Career
  • Vendor News
  • Jobs
  • Events
    • Webinars & Events
    • Submit an Event
  • Downloads
    • eBooks
    • Whitepapers
  • Podcasts
  • Videos
  • Subscribe
No Result
View All Result
Corporate Compliance Insights

GSK Settles SEC FCPA Case for $20 Million

by Michael Volkov
October 10, 2016
in Uncategorized
SEC forces GSK to bolster risk management and compliance

This article was republished with permission from Michael Volkov’s blog, Corruption, Crime & Compliance.

The SEC finished with the last nail in GSK China’s coffin by announcing a $20 million FCPA settlement for GSK’s violations in China.

The Justice Department declined to prosecute this case. In 2014, a Chinese court fined GSK $490 million for domestic bribery. GSK’s former China executive was given a three-year suspended sentence and deported. A number of Chinese nationals were given prison sentences of between two and four years.

The SEC’s action relied on some of the same conduct that formed the basis for China’s bribery enforcement action.

Between 2010 and 2013, GSK handed out to health care professionals and medical officials large amounts of gifts, improper travel and entertainment with little or no educational or training purpose, as well as shopping excursions, family and home visits and cash. The costs associated with these payments were recorded in GSK’s books and records as legitimate expenses.

GSK implemented a strategy to confer improper benefits on health care professionals and medical officials in order to increase sales of GSK products. The illegal program was supervised and operated by senior marketing and sales managers at GSK China, and condoned by regional and district managers.

GSK employed over 700 travel agencies to assist in the bribery scheme, using traditional tools for promoting bribery, including inflated and fake invoices. GSK spent $225 million on travel and planning services. GSK determined through test sampling that approximately 44 percent of the sampled invoices were inflated and approximately 12 percent were for events that did not occur.

GSK’s scheme was carried out through wholly owned subsidiaries and a joint venture owned 55 percent by GSK and 45 percent by a government-owned entity.

GSK had no controls in place to ensure that speaker fees were paid to health care professionals for authorized and legitimate speaking engagements. There was no system that verified the actual identity of a speaker.

Approximately $2.2 million of the total of $17 million spent on speaker fees in 2012 could not be confirmed as being spent on a verified health care professional.

GSK also engaged a local vendor to facilitate a national marketing program to provide tools to promote the storage of vaccines. The project was used, however, to funnel gifts, laptops, tablets and other electronic items to health care professionals. GSK spent approximately $2.3 million on this effort.

During this three-year period, internal audit and compliance reviews identified control deficiencies and evidence of improper payments. GSK failed to respond to these deficiencies and address the problem in China.

GSK’s remedial efforts have been ongoing since the problems were first discovered in 2013.  In fact, the China investigation spurred GSK to make a number of changes to its global practices, including the elimination of most payments to doctors, including speaker fees, and altering the compensation structure to eliminate sales incentives based on the number of prescriptions generated.

GSK also enhanced its global risk assessment process, strengthened its monitoring and risk assessment tools and expanded its global compliance organization.

The SEC required GSK to submit regular reports on the status of its remediation and implementation of compliance measures.


Tags: tone at the top
Previous Post

Can General Counsel and Compliance Officers Blow the Whistle?

Next Post

Disaster Recovery Failures: Learning from Others’ Mistakes

Michael Volkov

Michael-Volkov-leclairryan Michael Volkov is the CEO of The Volkov Law Group LLC, where he provides compliance, internal investigation and white collar defense services.  He can be reached at mvolkov@volkovlaw.com. Michael has extensive experience representing clients on matters involving the Foreign Corrupt Practices Act, the UK Bribery Act, money laundering, Office of Foreign Asset Control (OFAC), export controls, sanctions and International Traffic in Arms, False Claims Act, Congressional investigations, online gambling and regulatory enforcement issues. Michael served for more than 17 years as a federal prosecutor in the U.S. Attorney’s Office in the District of Columbia; for five years as the Chief Crime and Terrorism Counsel for the Senate Judiciary Committee, and Chief Crime, Terrorism and Homeland Security Counsel for the Senate and House Judiciary Committees; and as a Trial Attorney in the Antitrust Division of the U.S. Department of Justice. Michael also maintains a well-known blog: Corruption Crime & Compliance, which is frequently cited by anti-corruption professionals and professionals in the compliance industry.

Related Posts

illustration of mafia man in silhouette with red tie

The Mafia’s Jackpot: How Criminal Organizations are Profiting from COVID-19

January 22, 2021
stick figure pointing to compliance presentation

Compliance and Professional Development

January 21, 2021
groups of straight pins connected by colorful thread

Why Networking is Vital for Job Seekers

January 21, 2021
illustration of videoconference, screen and speech bubbles

New Risks as COVID-19 Forces Rapid Technology Adoption

January 21, 2021
Next Post
Ensuring security amid disaster recovery efforts

Disaster Recovery Failures: Learning from Others’ Mistakes

Access realtime data
Dynamic Risk Assessments with Workiva

Special Coverage

Special COVID page graphic

Jump to a Topic:

anti-corruption anti-money laundering/AML Artificial Intelligence/A.I. automation banks board of directors board risk oversight bribery CCPA/California Consumer Privacy Act Cloud Compliance communications management Coronavirus/COVID-19 corporate culture crisis management cyber crime cyber risk data analytics data breach data governance decision-making diversity DOJ due diligence fcpa enforcement actions financial crime GDPR GRC HIPAA information security internal audit KYC/know your customer machine learning monitoring ransomware regtech reputation risk risk assessment Sanctions SEC social media risk technology third party risk management tone at the top training whistleblowing
No Result
View All Result

Privacy Policy

Follow Us

  • Facebook
  • Twitter
  • LinkedIn
  • RSS Feed

Category

  • CCI Press
  • Compliance
  • Compliance Podcasts
  • Cybersecurity
  • Data Privacy
  • eBooks
  • Ethics
  • FCPA
  • Featured
  • Financial Services
  • Fraud
  • Governance
  • GRC Vendor News
  • HR Compliance
  • Internal Audit
  • Leadership and Career
  • Opinion
  • Resource Library
  • Risk
  • Uncategorized
  • Videos
  • Webinars
  • Whitepapers

© 2019 Corporate Compliance Insights

No Result
View All Result
  • Home
  • About
  • Articles
  • Vendor News
  • Podcasts
  • Videos
  • Whitepapers
  • eBooks
  • Events
  • Jobs
  • Subscribe

© 2019 Corporate Compliance Insights